Patent intelligence · US
US 10080720
Pharmaceutical composition containing docetaxel
Pharmaceutical composition containing docetaxel
Patent details — US 10080720
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 25, 2018
- Expiration
- Sep 20, 2038
- Applicant
- GAINIA (SHANGHAI) PATENT TECHNOLOGY LTD.
- Claims
- 5
- CPC classes
- A61K, A61K31/337, A61K47/34, A61K9/0019
Quick answer
US 10080720 (Pharmaceutical composition containing docetaxel) is held by GAINIA (SHANGHAI) PATENT TECHNOLOGY LTD.. Status: granted. Granted Sep 25, 2018. Expires Sep 20, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GAINIA (SHANGHAI) PATENT TECHNOLOGY LTD.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/337, A61K47/34, A61K9/0019, A61K9/1075, A61K9/146
More from GAINIA (SHANGHAI) PATENT TECHNOLOGY LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12370232
Use of polyphenol containing sugar cane extracts for preventing, improving or treating a skin condition
granted -
US 12201701
Vegetable oil-derived contrast agent with high stability and preparation method thereof
granted -
US 11730178
Extraction method
granted -
US 11311581
Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
granted -
US 11020365
Mixture of fatty acids for use in the treatment of inflammatory pathologies
granted -
US 10960000
Abuse resistant pharmaceutical compositions
granted -
US 10646523
Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
granted -
US 10213389
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
granted
Related coverage
Frequently asked questions
What is US patent 10080720?
US 10080720 (Pharmaceutical composition containing docetaxel) is held by GAINIA (SHANGHAI) PATENT TECHNOLOGY LTD.. Status: granted. Granted Sep 25, 2018. Expires Sep 20, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10080720?
GAINIA (SHANGHAI) PATENT TECHNOLOGY LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 27 pharmaceutical patents for this assignee.
When does US 10080720 expire?
Our index shows an expiration date of Sep 20, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.